表紙
市場調查報告書
商品編碼
410995

粒細胞巨噬細胞聚落刺激因子受體亞基Alpha:開發中產品分析

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha - Pipeline Review, H2 2019

出版日期: | 出版商: Global Markets Direct | 英文 73 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供以粒細胞巨噬細胞聚落刺激因子受體亞基Alpha為標的的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

粒細胞巨噬細胞聚落刺激因子受體亞基Alpha 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Bolder Biotechnology Inc
  • Genzyme Corp
  • Johnson & Johnson
  • OncBioMune Pharmaceuticals Inc
  • Pharmaxis Ltd
  • Savara Inc
  • Targovax ASA
  • XL-protein GmbH

藥物簡介

  • BBT-007
  • GIFT-7
  • molgramostim
  • molgramostim
  • molgramostim
  • ONCOS-102
  • Prostatac
  • PXS-2200
  • RSV感染疾病用組換蛋白質
  • sargramostim
  • 前列腺癌疫苗
  • XL-150

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC1926TDB

Summary:

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Granulocyte macrophage colony stimulating factor receptor subunit alpha also known as CD116 is a receptor for granulocyte macrophage colony-stimulating factor. It is a member of the cytokine family of receptors. It plays an important role in controls the production, differentiation, and function of granulocytes and macrophages.

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 4 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Respiratory, Infectious Disease, Toxicology, Dermatology, Gastrointestinal and Hematological Disorders which include indications Melanoma, Alzheimer's Disease, Lung Disease, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Respiratory Distress Syndrome, Appendicitis, Chemotherapy Effects, Chemotherapy Induced Neutropenia, Crohn's Disease (Regional Enteritis), Epithelial Ovarian Cancer, Lung Infections, Lung Injury, Malignant Pleural Mesothelioma, Metastatic Colorectal Cancer, Mild Cognitive Impairment, Mycobacterium Infections, Neurology, Peritoneal Cancer, Peritonitis, Radiation Injury, Respiratory Syncytial Virus (RSV) Infections, Skin Ulcers and Wounds.

The latest report Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha - Pipeline Review, H2 2019, outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
  • The report reviews Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Overview
    • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Companies Involved in Therapeutics Development
    • Aduro BioTech Inc
    • Bolder Biotechnology Inc
    • Celdara Medical LLC
    • Profarma
    • Savara Inc
    • Targovax ASA
    • XL-protein GmbH
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Drug Profiles
    • BBT-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMJG-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GVAX Vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • molgramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • molgramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • molgramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONCOS-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for RSV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sargramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sargramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XL-150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Products
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Discontinued Products
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 15, 2019: Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
      • Jul 08, 2019: Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in Anti-PD1 refractory melanoma
      • Jun 12, 2019: Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
      • Jun 03, 2019: Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination
      • May 23, 2019: Targovax to fully focus on ONCOS Oncolytic virus program
      • May 23, 2019: Targovax - approval and publication of supplemental prospectus
      • May 08, 2019: Savara Pharmaceuticals: Investigating GM-CSF in aPAP - A logical replacement of a dysfunctional protein
      • May 08, 2019: Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma
      • May 06, 2019: Savara announces Molgradex received Fast Track Designation by FDA for treatment of autoimmune pulmonary alveolar proteinosis
      • Apr 01, 2019: Savara initiates phase 2a clinical study of Molgradex for the treatment of NTM lung infection in people living with cystic fibrosis
      • Feb 11, 2019: First patient treated in dose expansion cohort of Targovax's ONCOS-102 trial in melanoma
      • Dec 12, 2018: Targovax presents at DNB 9th Annual Nordic Healthcare Conference
      • Nov 02, 2018: Savara completes enrolment for Phase Iia Molgradex trial
      • Oct 24, 2018: Bolder BioTechnology to present preclinical data of BBT-007 at Acute Radiation Syndrome Meeting
      • Oct 15, 2018: Savara completes enrollment in pivotal Molgradex impala clinical study for the treatment of aPAP
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Aduro BioTech Inc, H2 2019
  • Pipeline by Bolder Biotechnology Inc, H2 2019
  • Pipeline by Celdara Medical LLC, H2 2019
  • Pipeline by Profarma, H2 2019
  • Pipeline by Savara Inc, H2 2019
  • Pipeline by Targovax ASA, H2 2019
  • Pipeline by XL-protein GmbH, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019